andapharmahk@gmail.com

Three Breakthrough Advantages of Tirzepatide: The Science Behind Its Global Dominance

Leave a Comment / Industry Information /

Market data reveals Tirzepatide captured ‌35% of the GLP-1 agonist market‌ within 18 months of launch, while semaglutide growth slowed to 12%. This seismic shift stems from three revolutionary advantages: 1. Dual-Target Mechanism: Superior Metabolic Control‌ Molecular Advantage‌ Drug Target Pathway Activation Semaglutide GLP-1 monoagonist Single-pathway stimulation Tirzepatide GIP/GLP-1 dual agonist Synchronized glucose-insulin regulation Clinical […]

Three Breakthrough Advantages of Tirzepatide: The Science Behind Its Global Dominance Read More »

Demystifying Generic Drugs: Science, Standards & Public Health Impact

Leave a Comment / News /

China’s Rigorous Generic Drug Consistency Evaluation Explained‌ Since 2015, China’s National Medical Products Administration (NMPA) has implemented the landmark Generic Drug Consistency Evaluation program – a scientific framework ensuring all generic medications match their brand-name counterparts in quality, efficacy, and safety through four pillars of verification: 1. Pharmaceutical Equivalence (PE): Molecular Identity‌ Generics must demonstrate:

Demystifying Generic Drugs: Science, Standards & Public Health Impact Read More »

Four Core Strategies to Enhance GLP-1 Weight Loss Efficacy

Leave a Comment / Product /

Bridging the Clinical Reality Gap: Why Real-World Results Fall Short‌ Studies reveal that real-world weight loss with GLP-1 drugs averages just ‌50% of clinical trial results‌ (20% ideal vs. 9% observed). This gap stems from three critical factors: Poor Medication Adherence‌: >60% of patients discontinue treatment within 1 year Suboptimal Dosing‌: Only 19% reach target

Four Core Strategies to Enhance GLP-1 Weight Loss Efficacy Read More »

Shopping Cart